215 related articles for article (PubMed ID: 20188051)
1. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
3. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
Bonneville M; Scotet E
Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
[TBL] [Abstract][Full Text] [Related]
4. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
5. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
6. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
8. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
9. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
10. [New insights into cytotoxic effector cells].
Rey J; Olive D; Sébahoun G; O'Callaghan T; Costello RT
Bull Cancer; 2005 Nov; 92(11):935-43. PubMed ID: 16316827
[TBL] [Abstract][Full Text] [Related]
11. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Thompson K; Rogers MJ
J Bone Miner Res; 2004 Feb; 19(2):278-88. PubMed ID: 14969398
[TBL] [Abstract][Full Text] [Related]
12. γδ T cells develop, respond and survive - with a little help from CD27.
Born WK; O'Brien RL
Eur J Immunol; 2011 Jan; 41(1):26-8. PubMed ID: 21182073
[TBL] [Abstract][Full Text] [Related]
13. Links between innate and cognate tumor immunity.
Ghiringhelli F; Apetoh L; Housseau F; Kroemer G; Zitvogel L
Curr Opin Immunol; 2007 Apr; 19(2):224-31. PubMed ID: 17303400
[TBL] [Abstract][Full Text] [Related]
14. Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells.
Devilder MC; Allain S; Dousset C; Bonneville M; Scotet E
J Immunol; 2009 Sep; 183(6):3625-33. PubMed ID: 19710464
[TBL] [Abstract][Full Text] [Related]
15. gammadelta T cells in cancer immunotherapy: current status and future prospects.
Chiplunkar S; Dhar S; Wesch D; Kabelitz D
Immunotherapy; 2009 Jul; 1(4):663-78. PubMed ID: 20635991
[TBL] [Abstract][Full Text] [Related]
16. Large scale expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR gamma/delta+ T cell isolation kit".
Salot S; Bercegeay S; Dreno B; Saïagh S; Scaglione V; Bonnafous C; Sicard H
J Immunol Methods; 2009 Aug; 347(1-2):12-8. PubMed ID: 19465023
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
18. Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells.
Meraviglia S; Caccamo N; Salerno A; Sireci G; Dieli F
J Immunol; 2010 Aug; 185(3):1770-6. PubMed ID: 20592281
[TBL] [Abstract][Full Text] [Related]
19. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
20. Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.
Daguzan C; Moulin M; Kulyk-Barbier H; Davrinche C; Peyrottes S; Champagne E
J Immunol; 2016 Mar; 196(5):2219-29. PubMed ID: 26819204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
